Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -2.13% is 435% below its 5-year average of 0.64%, around the middle of its 5-year range (-25.88%–46.75%).
119.13% below its 12-month average of 11.14%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 9.27%.
EBITDA MARGIN
-2.13%
EBITDA MARGIN AVG TTM
11.14%
EBITDA MARGIN AVG 3Y
-1.75%
EBITDA MARGIN AVG 5Y
0.64%
EBITDA MARGIN AVG 10Y
4.40%
EBITDA MARGIN AVG 15Y
6.65%
EBITDA MARGIN AVG 20Y
8.54%
CURRENT VS TTM AVG
-119.13%
CURRENT VS 3Y AVG
-21.78%
CURRENT VS 5Y AVG
-435.35%
CURRENT VS 10Y AVG
-148.45%
CURRENT VS 15Y AVG
-132.03%
CURRENT VS 20Y AVG
-124.94%
Orthofix Medical Inc.
Market Cap
$383.34M
EBITDA Margin
-2.13%
TTM Avg
11.14%
3Y Avg
-1.75%
5Y Avg
0.64%
Market Cap
$380.60M
EBITDA Margin
-107.01%
TTM Avg
-86.79%
3Y Avg
-53.66%
5Y Avg
-431.14%
Market Cap
$389.64M
EBITDA Margin
-403.32%
TTM Avg
-429.38%
3Y Avg
-429.38%
5Y Avg
-429.38%
Market Cap
$374.07M
EBITDA Margin
-12.87%
TTM Avg
-20.20%
3Y Avg
-216.20%
5Y Avg
-209.97%
Market Cap
$398.05M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$398.58M
EBITDA Margin
-1.71%
TTM Avg
-2.46%
3Y Avg
-6.59%
5Y Avg
-11.17%
Market Cap
$365.97M
EBITDA Margin
-271.53%
TTM Avg
-418.08%
3Y Avg
-211.46%
5Y Avg
-940.00%
Market Cap
$402.34M
EBITDA Margin
-59.97%
TTM Avg
-74.12%
3Y Avg
-94.06%
5Y Avg
-94.06%
Market Cap
$359.46M
EBITDA Margin
-1371.56%
TTM Avg
-1336.69%
3Y Avg
-1827.03%
5Y Avg
-11314.18%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Orthofix Medical Inc. (OFIX) | $383.34M | -2.13% | 11.14% | -1.75% | 0.64% |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $380.60M | -107.01% | -86.79% | -53.66% | -431.14% |
| Kyverna Therapeutics, Inc. (KYTX)vs › | $389.64M | -403.32% | -429.38% | -429.38% | -429.38% |
| Canopy Growth Corporation (CGC)vs › | $374.07M | -12.87% | -20.20% | -216.20% | -209.97% |
| MapLight Therapeutics, Inc. (MPLT)vs › | $398.05M | N/A | N/A | N/A | N/A |
| Myriad Genetics, Inc. (MYGN)vs › | $398.58M | -1.71% | -2.46% | -6.59% | -11.17% |
| Opus Genetics, Inc. (IRD)vs › | $365.97M | -271.53% | -418.08% | -211.46% | -940.00% |
| Carlsmed, Inc. (CARL)vs › | $402.34M | -59.97% | -74.12% | -94.06% | -94.06% |
| Ocugen, Inc. (OCGN)vs › | $359.46M | -1371.56% | -1336.69% | -1827.03% | -11314.18% |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $356.50M | -122.86% | -149.66% | -152.47% | -125.05% |
Gross Margin
69.6%
EBITDA Margin
-2.1%
Operating Margin
-3.0%
Net Margin
-7.4%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 9.27% |
| 2026-03-31 | -0.10% |
| 2025-12-31 | 46.75% |
| 2025-09-30 | -1.23% |
| 2025-06-30 | 0.98% |
| 2025-03-31 | -6.81% |
| 2024-12-31 | 7.35% |
| 2024-09-30 | -1.07% |
| 2024-06-30 | -4.72% |
| 2024-03-31 | -6.89% |
| 2023-12-31 | -0.66% |
| 2023-09-30 | -5.52% |
| 2023-06-30 | -11.59% |
| 2023-03-31 | -25.88% |
| 2022-12-31 | -2.36% |
| 2022-09-30 | 2.23% |
| 2022-06-30 | 11.79% |
| 2022-03-31 | 4.92% |
| 2021-12-31 | -0.84% |
| 2021-09-30 | 6.85% |
| 2021-06-30 | 10.47% |
| 2021-03-31 | 5.13% |
| 2020-12-31 | 10.94% |
| 2020-09-30 | 12.71% |
| 2020-06-30 | -17.99% |
| 2020-03-31 | 13.53% |
| 2019-12-31 | 6.49% |
| 2019-09-30 | -10.25% |
| 2019-06-30 | 6.57% |
| 2019-03-31 | 1.88% |
| 2018-12-31 | 14.37% |
| 2018-09-30 | 7.74% |
| 2018-06-30 | 10.38% |
| 2018-03-31 | 11.26% |
| 2017-12-31 | 19.30% |
| 2017-09-30 | 13.31% |
| 2017-06-30 | 12.27% |
| 2017-03-31 | 10.70% |
| 2016-12-31 | 7.80% |
| 2016-09-30 | 12.34% |
| 2016-06-30 | 10.88% |
| 2016-03-31 | 7.72% |
| 2015-12-31 | 24.52% |
| 2015-09-30 | 6.36% |
| 2015-06-30 | 9.27% |
| 2015-03-31 | -7.56% |
| 2014-12-31 | 4.47% |
| 2014-09-30 | 6.95% |
| 2014-06-30 | 12.10% |
| 2014-03-31 | 8.36% |
| 2013-12-31 | -5.10% |
| 2013-09-30 | -11.16% |
| 2013-06-30 | 14.26% |
| 2013-03-31 | 9.00% |
| 2012-12-31 | 26.13% |
| 2012-09-30 | 22.64% |
| 2012-06-30 | 21.69% |
| 2012-03-31 | 19.36% |
| 2011-12-31 | 14.84% |
| 2011-09-30 | 20.01% |
| 2011-06-30 | 17.11% |
| 2011-03-31 | -14.89% |
| 2010-12-31 | 16.59% |
| 2010-09-30 | 17.39% |
| 2010-06-30 | 18.31% |
| 2010-03-31 | 26.90% |
| 2009-12-31 | 19.62% |
| 2009-09-30 | 17.17% |
| 2009-06-30 | 11.11% |
| 2009-03-31 | 12.19% |
| 2008-12-31 | 14.68% |
| 2008-09-30 | -218.45% |
| 2008-06-30 | 14.80% |
| 2008-03-31 | 15.26% |
| 2007-12-31 | -0.42% |
| 2007-09-30 | 20.10% |
| 2007-06-30 | 19.90% |
| 2007-03-31 | 18.84% |
| 2006-12-31 | 15.74% |
| 2006-09-30 | -31.80% |
| 2006-06-30 | 21.95% |
| 2006-03-31 | 19.03% |
| 2005-12-31 | 24.63% |
| 2005-09-30 | 23.18% |
| 2005-06-30 | 25.39% |
| 2005-03-31 | 24.72% |
| 2004-12-31 | 25.41% |
| 2004-09-30 | 25.47% |
| 2004-06-30 | 23.80% |
| 2004-03-31 | 23.07% |
| 2003-12-31 | 26.12% |
| 2003-09-30 | 20.31% |
| 2003-06-30 | 23.24% |
| 2003-03-31 | 23.60% |
| 2002-12-31 | 24.36% |
| 2002-09-30 | 23.98% |
